Regeneron Q2 2026: Revenue Jumps 17% to $4.3B, EPS Crushes Estimates, Dupixent Reaches $6B
REGN sits 33% above its 52-week low of $541.
Summary
Regeneron crushed Q2 2026 estimates with $4.29B in revenue (up 17% YoY) and non-GAAP EPS of $14.29, driven by record Dupixent, EYLEA HD, and Libtayo sales. The Sanofi Development Balance is fully repaid, boosting future profits, and full-year guidance was raised.
Key Events · Earnings and Guidance · REGN
-
Q2 Revenue and EPS Beat
Total revenues of $4.29B, up 17% YoY, and non-GAAP diluted EPS of $14.29, up 11% YoY, both significantly above consensus.
-
Dupixent Global Sales Hit $6B
Dupixent global net sales (recorded by Sanofi) reached a new all-time high of $6.0B, up 38% YoY, driven by strong demand and new indications.
-
EYLEA HD and Libtayo Surge
EYLEA HD U.S. net sales rose 52% to $596M; Libtayo global net sales grew 30% to $489M, both setting new records.
-
Sanofi Development Balance Fully Repaid
The Sanofi Development Balance was fully repaid as of Q2 2026, removing a drag on collaboration revenue and boosting profits starting Q3.
Analysis · REGN · Life Sciences
A massive Q2 beat saw Regeneron deliver revenue of $4.29B, 12% above consensus, and adjusted EPS of $14.29, nearly 40% above expectations. Dupixent global sales soared 38% to $6.0B, EYLEA HD U.S. sales jumped 52% to $596M, and Libtayo grew 30% to $489M. The Sanofi Development Balance was fully repaid, removing a drag on collaboration profits starting Q3. Full-year guidance for gross margin was raised, and R&D and SG&A ranges were tightened. This is a thesis-affirming quarter that demonstrates broad commercial momentum and pipeline progress, with approximately 50 clinical assets advancing.
At the time of this filing, REGN was trading at $717.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.